[1]刘 震,康用堂,谢地秀,等.信迪利单抗联合XELOX方案治疗晚期胃癌的近期疗效及安全性分析[J].医学信息,2024,37(20):100-103.[doi:10.3969/j.issn.1006-1959.2024.20.019]
　LIU Zhen,KANG Yongtang,XIE Dixiu,et al.Analysis of Short-term Efficacy and Safety of Sintilimab Combined with XELOX Regimen in the Treatment of Advanced Gastric Cancer[J].Journal of Medical Information,2024,37(20):100-103.[doi:10.3969/j.issn.1006-1959.2024.20.019]
点击复制

信迪利单抗联合XELOX方案治疗晚期胃癌的近期疗效及安全性分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年20期
页码:
100-103
栏目:
论著
出版日期:
2024-10-15

文章信息/Info

Title:
Analysis of Short-term Efficacy and Safety of Sintilimab Combined with XELOX Regimen in the Treatment of Advanced Gastric Cancer
文章编号:
1006-1959（2024）20-0100-04
作者:
刘 震1; 康用堂1; 谢地秀2; 王金香1
1.安福县人民医院肿瘤科，江西 安福 343200；2.安福县中医院肿瘤科，江西 安福 343200
Author(s):
LIU Zhen1; KANG Yongtang1; XIE Dixiu2; WANG Jinxiang1
1.Department of Oncology,Anfu County People’s Hospital,Anfu 343200,Jiangxi,China;2.Department of Oncology,Anfu County Hospital of Traditional Chinese Medicine,Anfu 343200,Jiangxi,China
关键词:
信迪利单抗; XELOX方案; 晚期胃癌; 近期疗效; 安全性
Keywords:
Sindilimab; XELOX regimen; Advanced gastric cancer; Short-term efficacy; Safety
分类号:
R735.2
DOI:
10.3969/j.issn.1006-1959.2024.20.019
摘要:
目的 探究信迪利单抗联合XELOX方案（奥沙利铂+卡培他滨）治疗晚期胃癌的近期疗效及安全性。方法 选取2022年1月-2023年8月安福县人民医院收治的晚期胃癌患者60例作为研究对象，按照随机数字表法分为研究组和对照组，各30例。对照组采用XELOX方案治疗，研究组采用信迪利单抗联合XELOX方案治疗。比较两组治疗后临床疗效、不良反应发生率、肿瘤标志物水平[甲胎蛋白（AFP）、糖类抗原153（CA153）、糖类抗原724（CA724）、癌胚抗原（CEA）、糖类抗原125（CA125）及糖链抗原19-9（CA19-9）]。结果 研究组临床治疗有效率高于对照组，不良反应发生率低于对照组（P＜0.05）；两组治疗后AFP、CA153、CA724、CEA、CA125、CA19-9水平低于治疗前，且研究组AFP、CA153、CA724、CEA、CA125、CA19-9水平低于对照组（P＜0.05）。结论 信迪利单抗联合XELOX方案治疗晚期胃癌的效果良好，有助于降低血清肿瘤标记物水平及不良反应发生率，值得临床应用。
Abstract:
Objective To investigate the short-term efficacy and safety of sintilimab combined with XELOX regimen (oxaliplatin+capecitabine) in the treatment of advanced gastric cancer.Methods A total of 60 patients with advanced gastric cancer admitted to Anfu County People’s Hospital from January 2022 to August 2023 were selected as the research objects. According to the random number table method, they were divided into study group and control group, with 30 patients in each group. The control group was treated with XELOX regimen, and the study group was treated with sintilimab combined with XELOX regimen. The clinical efficacy, incidence of adverse reactions and levels of tumor markers [alpha-fetoprotein (AFP), carbohydrate antigen 153 (CA153), carbohydrate antigen 724 (CA724), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and carbohydrate antigen 19-9 (CA19-9)] were compared between the two groups after treatment.Results The effective rate of clinical treatment in the study group was higher than that in the control group, and the incidence of adverse reactions was lower than that in the control group (P<0.05). After treatment, the levels of AFP, CA153, CA724, CEA, CA125 and CA19-9 in the two groups were lower than those before treatment, and the levels of AFP, CA153, CA724, CEA, CA125 and CA19-9 in the study group were lower than those in the control group (P<0.05).Conclusion Sindilimab combined with XELOX regimen is effective in the treatment of advanced gastric cancer, which is helpful to reduce the level of serum tumor markers and the incidence of adverse reactions. It is worthy of clinical application.

参考文献/References:

[1]郭芬,王玉,时建明,等.基于真实世界分析信迪利单抗联合化学治疗方案治疗晚期胃癌的临床疗效及安全性[J].中国药业,2023,32(17):111-115.[2]许沙沙.信迪利单抗联合改良DCF方案治疗晚期胃癌的临床研究[J].实用中西医结合临床,2023,23(5):13-16.[3]李娟,叶斯斯,韩春,等.免疫检查点抑制剂联合化疗抗血管生成药物二线治疗晚期胃癌及胃食管结合部腺癌患者的疗效分析[J].解放军医学院学报,2023,44(7):763-768. [4]李超明.替吉奥与信迪利单抗在晚期胃癌治疗中的临床疗效和安全性研究[J].中国医药科学,2023,13(14):146-149.[5]卫春燕,宋丽丽.信迪利单抗联合改良DCF方案治疗晚期胃癌的临床研究[J].检验医学与临床,2022,19(14):1970-1974.[6]钱琳,曾进浩,吴茂林,等.1例信迪利单抗治疗晚期胃癌致重症药疹的中西医结合治疗报告[J].川北医学院学报,2023,38(6):847-849.[7]李娟,叶斯斯,张鹏飞,等.信迪利单抗一线治疗晚期胃癌或胃食管结合部腺癌的疗效分析[J].武警医学,2023,34(6):476-480.[8]Karimi P,Islami F,Anandasabapathy S,et al.Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention[J].Cancer Epidemiol Biomarkers Prev,2014,23(5):700-713. [9]罗忠民,詹志翔.信迪利单抗联合XELOX方案治疗晚期胃癌的疗效及对血清肿瘤标志物的影响[J].医学理论与实践,2023,36(1):72-74.[10]毕琼,李江佩,曹赤,等.复方斑蝥胶囊联合XELOX化疗方案对胃癌术后患者的临床疗效[J].中成药,2019,41(9):2111-2114.[11]陈延群,莫海云.DOF方案与XELOX方案一线治疗进展期胃癌疗效对比[J].中华肿瘤防治杂志,2021,28(10):782-787.[12]陈守华,姚卫东,季从飞,等.SOX与XELOX方案对晚期胃癌患者血清肿瘤标志物及免疫功能的影响[J].肿瘤药学,2021,11(2):215-218,228.[13]陈守华,姚卫东,季从飞,等.SOX与XELOX方案对中晚期胃癌临床疗效及对血清肿瘤标志物和免疫功能影响[J].交通医学,2021,35(1):77-80.[14]王冬慧,郭芳,郭玮,等.参芪扶正注射液结合XELOX化疗方案对晚期胃癌肿瘤标志物的影响[J].中华中医药学刊,2021,39(12):225-228.[15]章海斌,丁晓娇,王练,等.甲磺酸阿帕替尼联合XELOX方案一线应用于晚期胃癌的疗效与安全性评价[J].蚌埠医学院学报,2023,48(2):170-173.[16]李红志,邵珊珊,邵卫玲,等.XELOX和FOLFOX化疗方案对中晚期胃癌患者生活质量的影响及毒副反应[J].川北医学院学报,2019,34(5):578-581.[17]许亚凤,李相勇,王亚萍,等.FOLFOX4联合紫衫醇脂质体与XELOX方案一线治疗晚期胃癌的疗效观察[J].现代消化及介入诊疗,2020,25(4):492-495.[18]温敏雅,盛倩,章国东.金龙胶囊联合XELOX化疗方案对胃癌患者生活质量及细胞免疫功能的影响[J].新中医,2021,53(19):152-155.[19]吴晓峰,王启平,黄慧.华蟾素胶囊联合XELOX方案治疗晚期胃癌的疗效及对患者免疫状态的影响[J].中国医院用药评价与分析,2019,19(2):195-196,199.[20]黄和,陈其余,周磊,等.XELOX方案联合肝动脉化疗栓塞治疗胃癌伴肝转移的有效性与安全性[J].中华普通外科杂志,2019,34(12):1048-1051.

更新日期/Last Update: 1900-01-01